GSK3915393
- Generic Name
- GSK3915393
Overview
No overview information available.
Background
No background information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
GSK3915393 Medication Report
Name: GSK3915393 English Name: GSK3915393
Description: GSK3915393 is a novel, small molecule inhibitor of transglutaminase 2 (TG2) being developed by GlaxoSmithKline (GSK).
Mechanism of Action: GSK3915393 works by inhibiting the TG2 enzyme. In the context of celiac disease, TG2 modifies gluten, which then triggers an immune response. By blocking TG2, GSK3915393 aims to prevent this immune reaction to gluten. In idiopathic pulmonary fibrosis (IPF), the role of TG2 is also being investigated in the fibrotic process.
Current Development Status:
- Idiopathic Pulmonary Fibrosis (IPF): Currently in Phase II clinical trials to evaluate its efficacy and safety in reducing the decline in lung volume in participants with IPF.
- Celiac Disease: Development for celiac disease has been discontinued by GSK. Phase I studies have been completed to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants and patients with celiac disease.
Route of Administration: GSK3915393 has been administered orally (capsules) and intravenously in clinical trials.
Clinical Trials: Several clinical trials have been conducted or are ongoing to evaluate GSK3915393:
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.